Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third‐ or Later‐Line Chemotherapy for CLDN18.2‐Positive and HER2‐Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol.
Saved in:
| Title: | Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third‐ or Later‐Line Chemotherapy for CLDN18.2‐Positive and HER2‐Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol. |
|---|---|
| Authors: | Maeda, Osamu1 (AUTHOR) maeda.osamu.s2@f.mail.nagoya‐u.ac.jp, Tanaka, Chie2 (AUTHOR), Furukawa, Kazuhiro3 (AUTHOR), Miyata, Kazushi4 (AUTHOR), Shimizu, Dai2 (AUTHOR), Sugita, Shizuki4 (AUTHOR), Nakanishi, Koki2 (AUTHOR), Hirose, Takashi3 (AUTHOR), Mizuno, Kazuyuki1 (AUTHOR), Kinoshita, Fumie5 (AUTHOR), Kuwatsuka, Yachiyo5 (AUTHOR), Ando, Masahiko5 (AUTHOR), Kanda, Mitsuro2 (AUTHOR), Kawashima, Hiroki3 (AUTHOR), Ando, Yuichi1 (AUTHOR) |
| Source: | Cancer Medicine. May2026, Vol. 15 Issue 5, p1-5. 5p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20457634 |
|---|---|
| DOI: | 10.1002/cam4.71981 |
